COMPASS Pathways PLC ADR (CMPS) News

COMPASS Pathways PLC ADR (CMPS): $16.96

-0.41 (-2.36%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter CMPS News Items

CMPS News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

CMPS News Highlights

  • For CMPS, its 30 day story count is now at 7.
  • Over the past 18 days, the trend for CMPS's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • The most mentioned tickers in articles about CMPS are DECK.

Latest CMPS News From Around the Web

Below are the latest news stories about COMPASS Pathways plc that investors may wish to consider to help them evaluate CMPS as an investment opportunity.

COMPASS Pathways plc 2021 Q4 - Results - Earnings Call Presentation

The following slide deck was published by COMPASS Pathways plc in conjunction with their 2021 Q4 earnings call....

SA Transcripts on Seeking Alpha | February 24, 2022

COMPASS Pathways announces financial results for the fourth quarter and full year 2021 and business highlights

LONDON, United Kingdom, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Highlights: Positive results from phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD); rapid and sustained response for patients receiving a single 25mg dose of COMP360 psilocybin with psychological supportPositive results from open-label study of 25mg COMP360 psilocybin therapy as adjunct to SSRI antidepressants in TRDLaunch of phase II study of COMP360 psilocybin therapy for post-traumatic stress disorder

Yahoo | February 24, 2022

COMPASS Pathways plc to announce fourth quarter and full year 2021 financial results on 24 February 2022

LONDON, United Kingdom, Feb. 17, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the fourth quarter and full year 2021, and provide an update on recent business developments on 24 February 2022.

GlobeNewswire | February 17, 2022

Why the Stock Market Is a Terrible Thermometer of Biotech Success

In this Backstage Pass segment, recorded on Feb. 4, Motley Fool contributor Rachel Warren discusses the psychedelic therapeutics market with Tim Schlidt, co-founder and partner at Palo Santo, a psychedelic investment fund. Schlidt explains that clinical milestones are the best way to gauge the health of this market going forward. Rachel Warren: What is one thing that we can all be watching to gauge the health of the psychedelic therapeutics market going forward?

Yahoo | February 17, 2022

Magic Mushroom''s Active Compound Could Relieve Depression For Up To One Year, New Study Finds

A new review study by Johns Hopkins University researchers is shedding light on the long-term effects of psilocybin in the treatment of major depression. In a new study, 58% of participants with major depressive disorder were in remission after one year of doing two sessions with psilocybin. “Psilocybin not only produces significant and immediate effects, it also has a long duration, which suggests that it may be a uniquely useful new treatment for depression,” said Roland Griffiths , Ph.D., Professor in Neuropsychopharmacology of Consciousness at Johns Hopkins School of Medicine. Psilocybin, also known as the active compound in “magic mushrooms,” is one of the compounds spearheading a pipeline that looks to advance psychedelic drugs for medical use. There are currently dozens of biotec...

Benzinga | February 16, 2022

Maxim Group Keeps a Buy Rating on COMPASS Pathways (CMPS)

In a report issued on February 2, Jason McCarthy from Maxim Group maintained a Buy rating on COMPASS Pathways (CMPS – Research Report), with a price target of $30.00. The company's shares closed last Friday at $14.85, close to its 52-week low of $13.69. According to TipRanks.com, McCarthy is ranked 0 out of 5 stars with an average return of -22.9% and a 14.7% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Reviva Pharmaceuticals Holdings, and Brainstorm Cell Therapeutics. COMPASS Pathways has an analyst consensus of Strong Buy, with a price target consensus of $79.75.

Howard Kim on TipRanks | February 6, 2022

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit for patients with treatment-resistant depression

London, UK and New York, US, 19 January 2022 COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and Sermo, a global leader in physician insights, today announced findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD). More than 320 milli

Yahoo | January 19, 2022

Compass Pathways: Zero Revenue, Shares May Head South

COMPASS Pathways (CMPS) is a mental health care company that accelerates patient access to evidence-based innovation in mental health. The company looks to find better ways of helping people suffering from mental health challenges. Some people do not benefit from existing therapies. CMPS is developing a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are poorly served by most treatments. CMPS has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.

Stavros Georgiadis on TipRanks | January 17, 2022

COMPASS Pathways to participate in H.C. Wainwright investor conference

LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the H.C. Wainwright BioConnect Virtual Conference, available on demand from 10 to 13 January. An audio webcast of the fireside chat will be available on the “Events” page of the Investors section of the COMPASS website. A replay of t

Yahoo | January 10, 2022

COMP360 psilocybin study of 89 healthy participants published in Journal of Psychopharmacology

Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, shared results today of a phase I study showing the feasibility of administering COMP360 psilocybin to up to six healthy participants simultaneousl

Yahoo | January 4, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.968 seconds.